Orphan Drugs: Small Is the New Big

Source: Medical Marketing & Media Deborah Weinstein (4/1/12)

"Big Pharma is used to thinking big, but more and more companies are turning to the rare diseases category and to conditions that affect patient groups with populations less than than some small towns."

Medical Marketing & Media Deborah Weinstein

Unsurprisingly, Big Pharma is used to thinking big. But Corcept and a host of other companies are beginning to focus on health stories that grab less boldfaced treatment. They are turning to the rare-diseases category and to conditions that affect patient groups with populations smaller than some small towns.

Inducements to find and develop drugs for so few people include incentives that go beyond the seven years of patent status under the 1983 Orphan Drug Act. These include government grants that can help defray the costs of clinical trials. The awards range from $200,000 to $400,000 per year depending on the trial phase.

Recent developments suggest progress, albeit uneven. In 2011, 14 new drugs, new formulations and products with new manufacturers were approved that had garnered FDA orphan drug status (including 10 new NMEs and BLAs), a head-over-heels improvement from 2010's total of zero, and a 367% improvement over 2009, when just three such drugs were sanctioned. . .View Full Article

LA Biotech's Lower Revenue Will Be Short Lived
Source: Dr. Jonathan Aschoff (04/17/2024)

While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out
Source: Streetwise Reports (04/08/2024)

After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (03/27/2024)

Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.

Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff (03/19/2024)

Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.

Biotech Stocks Break Out
Source: Ron Struthers (03/19/2024)

Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.